Articles

A cautionary tale - EU merger control rules may apply to pharma pipeline products

A cautionary tale - EU merger control rules may apply to pharma pipeline products

A cautionary tale - EU merger control rules may apply to pharma pipeline products

25.10.2016 NL law

In Case M.7872 – Novartis/GlaxoSmithKline (ofatumumab autoimmune indications), the European Commission claimed jurisdiction under the merger control rules over a transaction by virtue of which a yet to be fully developed biological drug was transferred to a purchaser. In applying the relevant jurisdictional test, the Commission made a series of observations which have far-reaching implications. 

This article has been published in Competition Law Insight,  20 September 2016. 

Read the article

Team

Related news

06.06.2019 NL law
Dutch court: insufficient substantiation? No follow-on cartel damages action

Short Reads - Dutch courts are forcing claimants (including claims vehicles) to be well-prepared before initiating follow-on actions. The Amsterdam District Court in the Dutch trucks cartel follow-on proceedings recently ruled that claimants – specifically CDC, STCC, Chapelton, K&D c.s. and STEF c.s. – had insufficiently substantiated their claims.

Read more

Our website uses functional cookies for the functioning of the website and analytic cookies that enable us to generate aggregated visitor data. We also use other cookies, such as third party tracking cookies - please indicate whether you agree to the use of these other cookies:

Privacy – en cookieverklaring